Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Prevalence and morbidity of urogenital schistosomiasis among pre-school age children in Cubal, Angola

  • Sánchez-Marqués, Raquel
  • Bocanegra García, Maria Cristina
  • Nindia, Arlette
  • Pintar, Zeferino
  • Aixut, Sandra
  • Martínez-Campreciós, Joan
  • Sulleiro, Elena
  • Espiau, María
  • Molina Romero, Israel
  • Salvador Velez, Fernando
Morbidity; Urine; Schistosomiasis, Morbilidad; Orina; Esquistosomiasis, Morbilitat; Orina; Esquistosomiasi, Background: Schistosomiasis is one of the most important neglected tropical diseases, with a great impact on public health and more than 200,000 deaths annually. Schistosoma haematobium causes urinary tract (UT) morbidity. Since schistosomiasis morbidity control programs focus on children older than 5 years, pre-school age children (PSAC) morbidity is not well known. Methods: We conducted a cross-sectional study in Cubal (Angola) among 245 PSAC with the objective of evaluating the prevalence of S. haematobium infection, the intensity of infection, and associated morbidity. For this purpose, urine filtration test followed by microscopic visualization and ultrasound examinations were performed. Results: The estimated overall prevalence of urogenital schistosomiasis was 30.2% (CI 95%; 24.5-35.9), with 20.3% (CI 95%; 15.3-25.3) of the samples analysed showing a high intensity of infection. A total of 54.5% (CI 95%; 47.6-61.8) of infected children presented UT lesions, showing a significant association between schistosomiasis infection and UT morbidity (p-value < 0.001). Bladder wall thickening was the most common lesion, being present in 100% of abnormal ultrasounds. We found that anaemia and severe malnutrition were not significantly associated with the development of UT lesions. Conclusions: S. haematobium infection in PSAC causes great UT detectable morbidities. Therefore, there is an evident need of including them in mass drug administration (MDA) campaigns and consequently the development of an adapted praziquantel treatment dosage for children under 2 years of age., This research was supported by the Red de Investigación de Centros de Enfermedades Tropicales–RICET (Grant No. RD16/0027/0023 and RD16/0027/0003) of the PN de I+D+I, ISCIII-Subdirección General de Redes y Centros de Investigación Cooperativa RETICS), Spanish Ministry of Health and Consumption; by CIBER de Enfermedades Infecciosas (Grant No. CB21/13/00056 and CB21/13/00029), ISCIII, Spanish Ministry of Science and Education; and by the PROMETEO Program, Programa of Ayudas para Grupos de Investigación de Excelencia, Generalitat Valenciana (Grant No. 2021/004).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Blastocystis sp. Carriage and Irritable Bowel Syndrome, Is the Association Already Established?

  • Salvador Velez, Fernando Maria|||0000-0002-0546-1354
  • Lobo Álvarez, Beatriz|||0000-0003-3391-7125
  • Goterris, Lidia|||0000-0003-1471-4461
  • Alonso Cotoner, Carmen|||0000-0002-3483-2919
  • Santos, Javier|||0000-0002-4798-5033
  • Sulleiro, Elena|||0000-0002-9783-6060
  • Bailo, Begoña|||0000-0002-9453-9431
  • Carmena, David|||0000-0002-4015-8553
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Bosch-Nicolau, Pau|||0000-0002-7435-1829
  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Fuentes, Isabel
  • Molina Romero, Israel|||0000-0001-6642-7515
The intestinal protist Blastocystis sp. is one of the most common intestinal parasites observed in humans, and has a worldwide distribution, being more prevalent in developing countries. Although this parasite has been described decades ago, the pathogenic potential it is still not understood completely. It has been suggested that Blastocystis sp. could be related with irritable bowel syndrome, a functional gastrointestinal disorder characterized by abdominal pain, discomfort with defecation, and changes in the frequency or form of stool. In our study, we compare a group of patients with irritable bowel syndrome with a group of healthy volunteers; no differences regarding the occurrence of Blastocystis sp. detection was found between both groups. Background: The aim of the present study is to describe the occurrence of Blastocystis sp. detection among asymptomatic subjects and patients with irritable bowel syndrome in order to evaluate the potential association between irritable bowel syndrome and the parasitic infection. Methods: Cross-sectional study where adult patients with irritable bowel syndrome diagnosed according to Rome IV criteria were included. A control group was formed by asymptomatic subjects older than 18 years. Exclusion criteria were: immunosuppressive condition or having received any drug with demonstrated activity against Blastocystis sp. within the last 6 months before study inclusion. Epidemiological and clinical information was collected from all included participants. Two stool samples were obtained from all participants: one sample for microscopic examination and one sample for Blastocystis sp. PCR detection. Blastocystis sp. infection was defined by the positivity of any of the diagnostic techniques. Results: Seventy-two participants were included (36 asymptomatic subjects and 36 patients with irritable bowel syndrome). Thirty-five (48.6%) were men, and median age of participants was 34 (IQR 29-49) years. The overall rate of Blastocystis sp. carriage was 27.8% (20/72). The prevalence assessed through microscopic examination was 22.2% (16/72), while the prevalence measured by PCR was 15.3% (11/72). When comparing the presence of Blastocystis sp. between asymptomatic subjects and IBS patients, we did not find any statistically significant difference (36.1% vs. 19.4% respectively, p = 0.114). Conclusions: regarding the occurrence of Blastocystis sp., no differences were found between asymptomatic participants and patients with irritable bowel disease irrespective of the diagnostic technique performed.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Prevalence and morbidity of urogenital schistosomiasis among pre-school age children in Cubal, Angola

  • Sánchez-Marqués, Raquel
  • Bocanegra García, Maria Cristina
  • Nindia, Arlette
  • Pintar, Zeferino
  • Aixut, Sandra
  • Martínez-Campreciós, Joan
  • Sulleiro, Elena
  • Espiau, María
  • Molina Romero, Israel
  • Salvador Velez, Fernando
Morbidity; Urine; Schistosomiasis, Morbilidad; Orina; Esquistosomiasis, Morbilitat; Orina; Esquistosomiasi, Background: Schistosomiasis is one of the most important neglected tropical diseases, with a great impact on public health and more than 200,000 deaths annually. Schistosoma haematobium causes urinary tract (UT) morbidity. Since schistosomiasis morbidity control programs focus on children older than 5 years, pre-school age children (PSAC) morbidity is not well known. Methods: We conducted a cross-sectional study in Cubal (Angola) among 245 PSAC with the objective of evaluating the prevalence of S. haematobium infection, the intensity of infection, and associated morbidity. For this purpose, urine filtration test followed by microscopic visualization and ultrasound examinations were performed. Results: The estimated overall prevalence of urogenital schistosomiasis was 30.2% (CI 95%; 24.5-35.9), with 20.3% (CI 95%; 15.3-25.3) of the samples analysed showing a high intensity of infection. A total of 54.5% (CI 95%; 47.6-61.8) of infected children presented UT lesions, showing a significant association between schistosomiasis infection and UT morbidity (p-value < 0.001). Bladder wall thickening was the most common lesion, being present in 100% of abnormal ultrasounds. We found that anaemia and severe malnutrition were not significantly associated with the development of UT lesions. Conclusions: S. haematobium infection in PSAC causes great UT detectable morbidities. Therefore, there is an evident need of including them in mass drug administration (MDA) campaigns and consequently the development of an adapted praziquantel treatment dosage for children under 2 years of age., This research was supported by the Red de Investigación de Centros de Enfermedades Tropicales–RICET (Grant No. RD16/0027/0023 and RD16/0027/0003) of the PN de I+D+I, ISCIII-Subdirección General de Redes y Centros de Investigación Cooperativa RETICS), Spanish Ministry of Health and Consumption; by CIBER de Enfermedades Infecciosas (Grant No. CB21/13/00056 and CB21/13/00029), ISCIII, Spanish Ministry of Science and Education; and by the PROMETEO Program, Programa of Ayudas para Grupos de Investigación de Excelencia, Generalitat Valenciana (Grant No. 2021/004).